Health Care

MESQUITE, NV, June 10, 2025 (GLOBE NEWSWIRE) -- Dogecoin Cash Inc. (OTCQB: CBDS), a publicly traded company operating at the intersection of digital assets and public equity markets, announced today that it has received approval to change its stock ticker symbol to DOGP, effective June 10, 2025. The new symbol better aligns with the company’s identity, mission, and growing role in the decentralized meme economy.

“This move marks our territory in the memeosphere,” said David Tobias, CEO of Dogecoin Cash Inc. “DOGP isn’t just a ticker — it’s a signal that we’re serious about building in the crypto culture and our commitment to real innovation with real compliance. It signals that we’re not only part of the conversation — we’re leading the barkstorm.”

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

DXS INTERNATIONAL PLC (AQSE: DXSP)

Ad hoc announcement pursuant to Art. 53 LR

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield “Hits”. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies.